Clinical trial
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to…
NCT00386516 · Galectin Therapeutics Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00386516 |
|---|---|
| Title | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer |
| Official title | Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer |
| Lead sponsor | Galectin Therapeutics Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of the Bile Duct, Gallbladder Cancer |
| Intervention type | Drug |
| Interventions | GM-CT-01, 5-Fluorouracil |
| Enrollment | 0 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Oct 11, 2006 |
| Last update posted | Aug 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: